Pictured: Genome.One CEO Marcel Dinger with MTPConnect Chair Sue MacLeman and MTAA CEO Ian Burgess in April 2018 at the launch of BioMedTech Horizons in Melbourne.
Precision cancer medicine is set to transform the clinical trial industry, with international trials attracting heavy investment. This next generation of clinical trials requires fast, comprehensive and cost-effective genomic profiling of patient tumours.
The FDA recently approved two US cancer genomic tests, however, their cost (AU$5,500) is prohibitive for routine use in Australia and their matching to US-approved drugs and trials are of limited utility to Australians. Offshore testing also fails to develop necessary domestic infrastructure for precision cancer clinical trials.
The genome-profiling platform for precision cancer medicine is set to include a clinically-accredited tumour profiling test and a cancer genomics data platform that incorporates a national patient matching system for precision cancer clinical trial access. It aims to provide competitively priced and rapid local testing. These solutions work to ensure that, in the face of increasing global capabilities and investment in precision cancer clinical trials, Australia will remain an attractive trial site and leader in precision medicine.
Visit Garvan Institute of Medical Research for more details.
LinkedIn: Garvan Institute of Medical Research
|Consortium lead||Garvan Institute of Medical Research|
|Consortium members||Genome.One & Illumina|
Professor David Thomas, Director of the Kinghorn Cancer Centre, Head of Genomic Cancer Medicine Program, Co-lead for the MoST Trial - firstname.lastname@example.org